Our research focuses on the development of new methods of organic synthesis and their implementation in the total synthesis of natural products, including cascade cyclizations and C–C bond forming processes. Today, as part of the Novartis-MIT Center for Continuous Manufacturing, we develop new technologies to replace the pharmaceutical industry's conventional batch-based system with a continuous manufacturing process that can improve reaction efficiency.

At the Innovative Technology Centre of Cambridge University, a new state-of-the-art flow chemistry academic facility, our group develops enabling continuous flow technologies for chemical synthesis. In addition, we specialize in developing new synthetic methods and applying them to the construction of biologically important molecules.

Our research group pursues catalysis applications for hydrogen storage, biomass conversion to chemicals and fuels, supported molecular catalysts for hydrocarbon transformations and green routes to fluorocarbons. As part of the Canada Research Chair in Catalysis Science for Energy Applications, we also develop new tandem catalysis processes for energy applications, sustainability and green chemical processes.

Our Laboratory for Methodologies and Synthesis of Natural Products aims at the development of new synthetic methodologies allowing for a rapid and efficient access to several complex molecular skeletons found in a lot of natural compounds.

Our research in molecular catalysis is directed towards the discovery of energy- and resource-frugal ways to build the molecules and materials that enable the advanced technologies of the 21st century, all for the sake of sustainability.

Our research is focused on developing new methods for the formation of C-C bonds, which plays an important role in the synthesis of many chemical structures, including drugs that are used to treat numerous diseases. Towards this end, we employ carboxylic acids and their mimics to create novel reactive groups that improve on transition-metal based coupling partners.

Our group develops simple, efficient, and general processes involving organometallic species with high relevance to the fields of pharmaceutical, agrochemical or material sciences. Our main objective is to explore and extend the reactivity of organobismuthanes and to apply the discoveries in the arena of C-N, C-O, and C-C bond formation.

Our research group develops simple and efficient synthetic methodologies of broad use. Our main approach focuses on a dynamic interaction between experimental and computational studies.

Our research involves the design of new reactions, methods and processes for the synthesis of important organic molecules. Transition metal catalysis, flow chemistry, and green chemistry strategies are heavily utilized towards this goal. Emphasis is made onindustrially relevant reactions that could be of direct use to the pharmaceutical, polymer, biomass, and bulk chemical industries.

Our group develops novel synthetic methodologies through transition metal catalysis, with an emphasis on the preparation of organofluorine compounds. These new processes are then used to synthesize bioactive molecules or compounds with therapeutic interest.

Our research is aimed at modifying enzymes, particularly in their active sites, and overcoming resistance to antibiotics in order to provide new industrial applications in biocatalysis and green chemistry and ultimately increase our understanding of enzyme catalysis.

Our research exploits organic, bio-organic and supramolecular chemistry in order to gain insight into how molecular recognition and motion can be combined for the development of new catalytic systems and new transmembrane transporters.

Delmar is a bulk API and specialty chemical company, which provides a broad spectrum of chemistry services, including the development of highly complex syntheses process optimization. Its chemists can provide technical assistance in the early stages of any drug development program, from creating a process for a new compound to refining an existing lab-scale procedure. As it produces metric tons of chemical products annually, it is eager to introduce continuous flow techniques into its manufacturing process.

Magnus Chemicals is a specialized chemistry company, which is focused on providing integrated and efficient solutions for water management (treatment, purity, and decontamination). For undesirable liquid and solid separation, the company takes into account the multiple physical and chemical parameters in the water processing, all of which can easily be handled by continuous flow approaches.

Committed to improving the health and well-being of human kind, Merck is a global health care leader with a diversified portfolio of prescription medicines, vaccines, and animal health products. Its research sites, particularly the ones in Rahway, NJ and Cambridge, MA (with which CREATE members have close interactions) are becoming heavily involved in integrating continuous flow technologies into their R&D program, in both process and medicinal chemistry.

OmegaChem is a privately owned Canadian company, which specializes in providing the chemical and pharmaceutical industry with expertise in sourcing, developing and manufacturing custom-made synthetic intermediates as well as supplying a wide range of fine chemicals. Today, with its activities serving customers worldwide, the use of continuous flow processes is anticipated to become very important in its future R&D program.

Paraza Pharma is a biotech company, which aims to significantly improve the efficiency of the drug discovery process from lead identification through lead optimization to development candidates. It is a developer of pharmaceutical property-enriched small molecule drug libraries derived from marketed drugs and is exploring continuous flow science as a way to facilitate the manufacturing of important building blocks.